Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2024 · 10-Q
Revenue$981.86K$981.86K−80.9% vs Q3 2023 Net Income-$4.72M-$4.72MN/M vs Q3 2023 EPS Diluted-$3.55-$3.55N/M vs Q3 2023 Gross Profit$291,019−77.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,645,403N/M Margins · derivedGross margin29.6%+4.4 pt vs Q3 2023
Operating margin-271.9%−187.8 pt vs Q3 2023
Net margin-480.7%−370.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 15, 2024 · 46 d after period end